Sygnature Discovery Limited

Sygnature Discovery is a leading independent provider of integrated drug discovery resource and expertise. Since 2011, 31 compounds discovered by Sygnature for clients have entered pre-clinical development and so far 15 of these have progressed to clinical trials (Phases I, II and III). We add considerable value to our clients'​ research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimization and drug discovery programmes.

Sygnature's capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, and protein crystallography (via affiliate company Peak Proteins). We can also provide pre-clinical experimental services support through our sister company RenaSci. Sygnature Discovery operates a business whose primary focus is value creation for our clients, through the application of integrated drug discovery know-how and close working relationships. We have built a team of over 200 pharmaceutical industry-experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.

In summary, Sygnature Discovery offers:

• Target validation
• Hit identification
• Hit-to-lead
• Lead optimization
• Integrated drug discovery programs
• Medicinal chemistry
• In vitro biology (including biophysics and live cell imaging)
• Computational chemistry
• DMPK
• Protein crystallography